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Abstract To analyze the possible involvement of c-ski and c-sno 
during the course of in vitro myogenesis, expression of their 
transcripts during differentiation of a murine muscle cell line 
(C2C12) was monitored by competitive reverse transcription- 
polymerase chain reaction (RT-PCR). The transcripts of c-snoN 
were temporarily increased 25-fold above basal level at 12 h prior 
to the onset of transcription of muscle-specific gene, e.g. 
myogenin and muscle creatine kinase, whereas c-ski was 
expressed invariably. The transient increase of c-snoN was 
blocked when myogenesis was interrupted by the presence of fetal 
calf serum in culture medhnn, probably due to growth factors 
being included; basic iibroblast growth factor (b-FGF) blocked 
the transient increase whereas epidermal growth factor (EGF) 
did not, consistent with the inhibitory effect of b-FGF and no 
effect of EGF on myotnbe formation of C2C12. In Rbroblastic 
C3HlOT112 cells, snoN exhibited a similar transient increase of 
transcript when growth arrested under the same conditions as for 
in vitro myogenesis, indicating that the expression of snoN is not 
sufftcient to induce the onset of muscle differentiation and an 
unknown factor involved in myogenic cells is necessary. The 
transient increase of suoN transcript may represent a common 
entrance step of cells into the GO phase where muscle 
differentiation is substantiated, considering that it was observed 
upon growth arrest of Rbroblastic C3HlOT112 cells and prior to 
the elevation of MCK in C2C12 but undetected when entry into 
GO was blocked by b-FGF. 
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1. Introduction 
The nuclear oncogene, v-ski was isolated from the Sloan- 
Kettering viruses (SKV) which are acute transforming avian 
retroviruses[l]. The 1.3 kb v-ski cDNA encodes a truncated 
form with deletion of both the N- and C-termini of the cel- 
lular counterpart, c-ski [2]. Like v-ski, c-ski and c-snoN (ski- 
related gene) induce not only morphological alteration and 
anchorage-independent growth but also terminal muscle dif- 
ferentiation in quail embryo cells when overexpressed [3-51, 
although c-ski and c-snoN mRNAs are not exclusively ex- 
pressed in muscle cells but widely expressed in many different 
tissues [6,7]. The muscle differentiation induced by overexpres- 
sion of c-ski accompanies the induction of MyoD and myo- 
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genin expression and fusion of myoblast to form multi-nu- 
cleated myotubes [8]. The hypertrophic effect on the skeletal 
muscle of transgenic mice by a transgene of a truncated c-ski 
cDNA also suggests the possible involvement of ski in the 
process of myogenesis [9]. However, little is known about 
the physiological implication of c-ski and c-snoN in the pro- 
longed process leading to myogenesis. 
In vitro myogenesis provides a suitable model for analysis 
of the regulatory mechanism controlling the antagonism be- 
tween cell growth and differentiation. Entry into quiescent 
state (GO) is necessary for myogenic cells to express muscle- 
specific proteins [lo]. MCK expression during myogenesis 
could be, therefore, regarded as a molecular marker indicating 
that the cells are present in the GO portion [lo]. 
The aim of this study was to examine whether c-ski or c- 
snoN regularly participates in the process leading to muscle 
differentiation. The mRNA levels of c-ski and c-snoN were 
monitored during in vitro myogenesis of the skeletal muscle 
cell line C2C12 and in a quiescent state of fibroblast 
C3HlOT112 cells. Reverse transcription-polymerase chain re- 
action (RT-PCR) was used to detect low abundance of the c- 
ski and c-snoN mRNAs. Analysis revealed that the amount of 
c-ski mRNA remained at a constant level throughout the 
myogenic process, while that of c-snoN mRNA increased tem- 
porarily prior to the onset of transcription of myogenin and 
muscle creatine kinase, followed by rapid down-regulation to 
basal level. b-FGF suppressed the transient expression of 
snoN and myotube formation of C2C12 cells whereas EGF 
suppressed neither. Consequently, transient expression of 
snoN was observed prior to the expression of MCK (GO 
marker) in differentiation-induced C2C12 and growth-arrested 
lOT1/2 cells but was lost when entry into GO was blocked by 
b-FGF. The signal mediating the Gl to GO transition remains 
unknown. The possible involvement of snoN in the Gl to GO 
transition will be discussed. 
2. Materials and methods 
2.1. Cell culture and growth .factors 
The C2C12 [11,12] and C3HlOTlR cells were maintained and dif- 
ferentiated as described elsewhere 1131. EGF (Uustate Biotechnologv 
Inc.) and b-FGF (Austral BiologiEali) were added to differentiation 
medium at 10 nM where indicated. 
2.2. RNA isolation and Northern blot analysb 
Total RNA was isolated and Northern blot analysis was performed 
as described 113-151. 20 ug of alvoxalated RNAs were electrouhoresed 
L  _  . I  
and transferred to Hybond N;,-a positively charged nylon membrane 
(Amersham). The following probes were used for hybridizations: (1) 
for the mouse muscle creatine kinase (MCK) cDNA probe, a 1143 bp 
BafllBalI fraffment from pMCKm36 [16]; (2) for the mouse MyoDl 
probe, an about 800 bp HpaIIIEcoRI fragment encoding the 3’ end 
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sequence of pEMClls cDNA [17]; and (3) a rat myogenin probe 
generated by PstI digestion of rat myogenin cDNApBSml3- 
MGN#l 1 [18]. cDNA probes were radiolabeled to a specific activity 
of 5~ lo8 cpm/ug with [cx-32P]dCTP (10 uCi/ul, Amersham) by the 
random priming method [ 191. 
The probes were stripped from the membranes for reuse by boiling 
for 20 min in 0.01 X SSC 0.1% SDS. Filters were exposed to an imag- 
ing plate of a BAS2000 system (Fuji Film Co.) and quantified. 
2.3. RT-PCR and DNA sequencing 
Oligonucleotide primers specific for human c-ski, snoN, snoA [7], 
and mouse c-ski and snoN were prepared on a DNA synthesizer 
(Applied Biosystems, model 381A). The primers employed were the 
following oligonucleotides: 5’ oligo, 5’-GAGGTGGAAGTTGAAA- 
GCAGG-3’ and 3’ oligo, 5’-TCATGCAGGAACTTCTCTTTGG-3’ 
for human ski; 5’ oligo, 5’-GAGAAGTTTAGCATGAGAAGTGG- 
3’ for human snoA and snoN; 3’ oligo, S’-GTTCCTCAAGTGAGA- 
CATCTGG-3’ for human snoN and 3’ oligo, 5’-CTGCAATACAAA- 
TATATCAATCGG-3’ for human snoA. The mouse mimers were as 
follows: 5’ oligo, 5’-TTGTCCTCGCTGTCCTCTCCG-3’ and 3’ oli- 
go, 5’-TGCCGCAGGTGCTCCAACTCT-3’ for mouse ski; 5’ oligo, 
S’GAGAATCCAATCAAAGACAGATACAC-3’ and 3’ oligo, 5’- 
GCTGACTACTCTCATGAGGCTT-3’ for mouse snoN. 1 ug of to- 
tal RNA from the indicated culture was reverse-transcribed using 
Molony murine leukemia virus (MMLV) reverse transcriptase (Gib- 
co-BRL) and random hexamer primers. An aliquot of the first strand 
of cDNA was amplified using Amplitaq DNA polymerase (Perkin 
Elmer) in a Programmable Incubator (Rikoh Kagaku Lab., Inc). 
The reaction conditions were as follows: one cycle of denaturation 
for 10 min at 94”C, 35 cycles of amplification (1.7 min denaturation at 
94°C I .7 min primer annealing at 60°C and 1.8 min polymerization at 
72°C for each step) and extension at 72°C for 10 min. 
For competitive PCR, competitor DNA was constructed from 
snoN-PCR product (325 bp) derived from C2C12 cells by insertion 
of an irrelevant short stretch of nucleotides (185 bp, intervening se- 
quence obtained from the B-lactamase gene carried by pBluescriptI1 
KS(+) plasmid). PCR-mediated amplification of snoN using specific 
primers generated the 257 bp DNA fragment from endogenous tem- 
plate and the 442 bp fragment from competitor DNA which was 
added before the start of the PCR reaction. The ratios of the 257 
bp to 442 bp product were compared with the time course of in vitro 
myogenesis of C2C12. Amplified DNA fragments were cloned into 
pBluescriptI1 KS(+) (Stratagene) for double-stranded sequencing 
with Sequenase Ver. 2.0 (USB Co.). GAPDH included in cDNA 
was also determined using a commercially available PCR primer 
(Clontech Lab.) as an internal control for normalization of snoN 
products. 
3. Results 
Since the amounts of the c-ski and c-snoN transcripts were 
not sufficient to be detected by Northern blot analysis, com- 
petitive RT-PCR was applied to detect and analyse the ex- 
pression profile. To design PCR primers for mouse c-ski and 
c-snoN mRNAs, the cDNAs of which have not yet been se- 
quenced, known sequences of human counterparts were used 
for making the putative PCR primer [7]. For prevention of 
cross-amplification between ski and snoN sequences, the ski- 
and snoN-specific primers used in this RT-PCR reaction were 
designed to generate specific portions encoded in exon 6 of c- 
ski and in exon l-5 of snoN, respectively. An alternatively 
spliced form of ~120 gene, sno1 mRNA was reported to be 
accumulated specifically in human skeletal muscle [20]. The 
specific primers for mouse snoN used in this study were avail- 
able to detect mouse sno1, but the predicted-sized PCR pro- 
duct from snoI insertion could not be detected as was the case 
for chicken sno [21]. The sequences of the PCR products using 
this putative primer and the cDNA template from mouse 
C2C12 cells were compared with the corresponding sequences 
of the human counterparts. The DNA sequence homology 
with human counterparts was found to be 85.4% identical 
for c-ski and 82.9% for c-snoN, respectively (data not shown). 
Considering the high score of the identity, the DNA sequences 
of the PCR products were regarded as representing endogen- 
ous mouse c-ski and c-snoN, respectively. These sequen- 
ces were therefore used to design the authentic primers 
of PCR for endogenous c-ski and c-snoN in mouse skeletal 
muscle cell line C2C12 as indicated in Section 2. A transient 
rise of snoN expression abruptly took place with a peak at 
12 h and had disappeared by 36 h after induction of muscle 
differentiation of C2C12, while ski was being expressed 
invariably (Fig. 1) and snoA was not detected (data not 
shown). 
Muscle differentiation is blocked by the presence of 10% 
fetal bovine serum (FBS) in culture medium even after growth 
arrest at confluence [22]. Along with interruption of myogen- 
esis in the presence of 10% FBS, the specific expression of 
snoN was also absent while ski remained to be expressed 
constantly (Fig. 2). Some growth factors included in serum 
may represent the inhibitory effect on both myogenesis and 
snoN expression. To assess this possibility, the effects of 
growth factors of which the receptors have tyrosine kinase 
activity on the mutinucleated myotube formation of C2C12 
and snoN expression were determined. EGF and basic 
FGF have a typical effect on myoblast fusion (Fig. 3A) and 
snoN expression (Fig. 3B). When myotube formation was 
interrupted by b-FGF, snoN ceased to appear. Prevention 
of myogenesis by b-FGF is due to the block of entry into 
GO [lo], suggesting that snoN expression may be linked 
to the Gl to GO transition. EGF had no effects on either 
of the two events, myoblast fusion (Fig. 3A) and snoN- 
expression (Fig. 3B) with a delay in peak formation. Thus, 
a correlation is suggested to exist between snoN expression 
and myotube formation. 
The fibroblastic cell line C3HlOTU2 is incapable of differ- 
entiation toward myogenesis, unless A4yoD family gene is 
overexpressed under the strong promoter. When growth-ar- 
rested C3HlOTU2 cells at confluence were exposed to the 
same differentiation conditions as for myogenesis of C2C12, 
typical snoN expression was observed with a delayed peak at 
24 h relative to the case for C2C12 cells (Fig. 4). This result 
means that snoN expression is insufficient to direct cells to- 
ward myogenesis in contrast to MyoD family protein. Some 
unknown factors downstream of snoN are needed for myo- 
genesis, existing in myoblasts but not in fibroblasts. Further- 
more, snoN expression is not exclusively observed in myogen- 
esis but is also evident in the process leading to the quiescent 
state (GO) of non-myogenic lOT1/2 cells. 
The expression profiles of c-ski and c-snoN in the course of 
in vitro myogenesis of C2C12 cells were compared with those 
of mRNAs of MyoD, myogenin, MCK and pyruvate kinase 
detected by Northern blot analysis (Fig. 5). While a house- 
keeping gene, pyruvate kinase retained a constant expression 
level in every case examined (data not shown), muscle-specific 
genes being up-regulated during C2C12 differentiation. MyoD 
was expressed even in growing cells. By contrast, myogenin 
transcript was not detected until differentiation had been trig- 
gered by the depletion of serum mitogens. A peak in the 
transient snoN expression emerged prior to the expression 
peaks of the muscle-specific transcription regulators, myogen- 
in and MyoD as well as muscle-specific marker, MCK which 
is expressed during GO [lo]. 
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Fig. 1. Expression patterns of mouse endogenous c-ski and c-snoN during C2Cl2 differentiation. RT-PCR analysis of mouse c-ski and c-snoN 
expression during differentiation of C2C12 cells. Total RNA (1 Kg) was extracted from C2Cl2 cells harvested at the indicated time of differen- 
tiation. cDNAs were obtained by reverse transcription, and then an aliquot was subjected to PCR as described in Section 2. PCR products 
were analyzed by 6% PAGE (upper panel: left, snoN; right, ski). Molecular weight standard (marker 4, Nippon Gene Co.) was applied on the 
rightmost and leftmost lanes. To compare m-snoN expression in independent reaction tubes, each amount of m-snoN products normalized with 
that of control fragment (designated as a competitor). Relative amounts at each time were determined against that at 0 h which is regarded as 
1 (lower panel: left, snoN; right, ski). 
times(br) atler induction of myogenesis. times@) after induction of myogenek 
Fig. 2. Expression patterns of endogenous c-ski and c-snoN in C2C12 cells when differentiation was blocked in the presence of 10% FBS. 
C2C12 cells were allowed to grow to confluent cell density and growth-arrested, then exposed to fresh 10% FBS-containing growth medium 
(DMEM) in place of differentiation medium. Time (h) after exposed to fresh medium is indicated on the bottom. Competitive PCR was carried 
out under the same condition as described in Fig. 1 and Section 2. Endogenous mouse GAPDH was amplified by PCR as an internal standard. 
Each amount of the PCR product of snoN (left) or ski (right) was normalized with those of endogenous GAPDH and competitor DNA 
(snoN). Relative amounts at each time were determined against that at 0 h which is regarded as 1. 
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Fig. 3. Effects of growth factors on c-ski and c-snoN expression. After C2C12 cells were allowed to grow to confluent density, culture medium 
was changed from growth medium to differentiation medium containing 2 nM EGF or 2 nM FGF. (A) Phase-contrast microscopic observa- 
tions of C2C12 cells in the presence of EGF or b-FGF. Times (h) after exposure to differentiation medium with or without 2 nM b-FGF or 
2 nM EGF are indicated at the top. (B) Competitive PCR was carried out and each amount of the PCR product of snoN (left) or ski (right) 
was normalized with those of GAPDH and competitor DNA (snoN). Relative amounts at each time (hours after exposure to differentiation 
medium) were determined against that at 0 h which is regarded as 1. 
4. Discussion 
Although c-ski and the related c-snoN proteins possess ac- 
tivitks to induce in vitro myogenesis of fibroblastoid embryo 
cells [3,4] and a truncated version of the c-ski transgene exerts 
a hypertrophic effect on skeletal fast muscle in transgenic mice 
[9], it remains unknown as to how endogenous ski or sno is 
expressed and functions during differentiation of the cells 
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Fig. 4. Expression pattern of endogenous c-ski and c-snoN in C3HlOT1/2 cells when exposed to differentiation condition. C3HlOT112 cells at 
confluent density were exposed to differentiation condition. (A) Competitive RT-PCR was carried out using total RNA extracted from 
C3HlOT1/2 cells harvested at the indicated time and analysed by 6% PAGE. The numbers at the top of the gel denote times (h) after the cells 
at confluent density were exposed to differentiation condition. Lane M, molecular weight standard; lane C, PCR products from competitor 
DNA alone. PCR product of competitor DNA showed ladder for unknown reason. (B) Each amount of the PCR products of snoN (left) or 
ski (right) was normalized with those of GAPDH and competitor DNA (snoN). Relative amounts at each time (hours after exposure to differ- 
entiation medium) were determined against that at 0 h which is regarded as 1. 
naturally destined to become skeletal muscle. A considerable 
time is required to reach the onset of myogenesis, e.g. it takes 
12 h for the expression of myogenin to begin (Fig. 5). Some 
unknown cryptic process must be included in the delay. This 
study describes time-dependent alterations of ski and snoN 
expression during the prolonged process leading to myogen- 
esis of cultured myogenic cells. 
By utilizing the RT-PCR technique, a transient increase of 
snoN mRNA upon serum depletion appeared earlier than the 
transcriptional regulator genes, e.g. MyoD and myogenin. 
Such transient expression is observed during phase transition 
of the cell cycle; cyclins [23], cdc2kinase [24] and c-fos [25] 
show similar transient expression. Therefore, the transient ex- 
pression of c-snoN may represent an unknown phase transi- 
tion state of the process from the growth to differentiation 
phase. Cells only arrested at GO but not other points of Gl 
phase are competent to express muscle-specific protein [lo]. 
The expression of MCK is, therefore, a marker to indicate 
the arrest of cells at GO [lo]. The expression of MCK as a 
GO marker initiated approximately at the peak of snoN ex- 
pression and did not accumulate maximally until the level of 
snoN mRNA had returned to basal, suggesting that snoN 
expression is positioned at the GllGO boundary where snoN 
may transmit a signal to advance the Gl to GO transition. 
Exposure of myogenic cells to high concentrations of serum or 
the purified b-FGF blocked and repressed the progress of the 
differentiation program but failed to induce cell proliferation 
[26] since b-FGF functions to induce the exit of cells from the 
258 
coniluent fUS.lOll myotube 
times(b) after induction of myogeaeh 
Fig. 5. Schematic representation of the expression pattern of snoN 
as compared with those of markers for myogenesis. Comparison be- 
tween expression profiles of endogenous snoN mRNA and other 
muscle-specific gene transcripts during C2C12 differentiation sched- 
ule. Northern blot analysis was performed with 20 f.tg of total RNA 
from C2C12 cells harvested at the indicated times after the cultures 
were exposed to the differentiation condition. 
GO portion of the cell cycle and arrest at approx. 4-6 h in the 
Gl phase [lo]. When the entry of C2Cl2 into GO was blocked 
by b-FGF at 10 nM, a concentration which completely inhib- 
ited myotube formation, the transient expression of snoN dis- 
appeared (Fig. 2). In contrast, since EGF functions as a pro- 
gression factor to mediate the Gl- to S-phase transition but 
not to induce the Gl/GO phase transition [27] and does not 
inhibit myotube formation, the entry of cells into the GO state 
occurs regularly and snoN is expressed normally, accompany- 
ing the delay and attenuation of the peak (Fig. 3). Transient 
expression of snoN was also observed when fibroblastic 
C3HlOT1/2 cells became quiescent (entry to GO) by serum 
deprivation and contact inhibition of cell growth at confluent 
cell density. This suggests that the transient snoN expression 
is related to the Gl to GO phase transition rather than the 
initial event for the programmed schedule of myogenesis. 
bFGF directly inhibits MyoD family proteins through protein 
kinase C-mediated phosphorylation [28]; therefore, there is no 
evidence that the loss of snoN expression is a direct cause of 
the failure to undergo myogenesis. Rather, it should be related 
to the inability to enter GO. The induction of in vitro myo- 
genesis of quail embryo cells by overexpression of snoN [4] 
would be due to the increase in cells at GO. Considering a 
transient increase of snoN was absent when entry to GO was 
blocked by exposure to b-FGF but is maintained when ex- 
posed to EGF which was unable to block the Gl to GO phase 
transition, a transient increase characteristic of snoN expres- 
sion upon serum deprivation may represent a molecular mar- 
ker for entry to the GO phase. c-fos was also transiently ex- 
pressed upon reinitiation of cell growth (exit from GO to Gl) 
with an immediate early response within minutes of growth 
factor stimulation [29,30]. In contrast, it takes approx. 12 h 
for snoN to be expressed maximally, suggesting the entry 
from Gl to GO is a time-consuming process relative to exit 
from GO. Two AUUUA sequences on the 3’ non-coding re- 
gion in c-snoN mRNA (chicken) [4] may cause relatively rapid 
degradation. Endogenous snoA mRNA was undetected in 
C2C12 cells. SnoA has not been detected in transcripts and 
genomic DNA in chicken [4]. Therefore, snoN is a dominant 
form of sno in mouse as in chicken. 
Consistent with the results demonstrated in avian myogenic 
QM7 cells and non-myogenic QM5 cell [31], no transient ex- 
pression of c-ski was observed during myogenesis of mouse 
myogenic C2C12 cells and when non-myogenic C3HlOT1/2 
cells was exposed to the condition for myogenesis (right pan- 
els in both Figs. 1 and 4). In mouse myeloid cells, ski mRNA 
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showed transient expression in mid Gl and snoN mRNA was 
expressed maximally in early to mid Gl [32]. Our results also 
showed that snoN transcript was expressed at a point of Gl 
prior to the entry to GO although it is impossible to specify 
the point of snoN expression at Gl exactly. The transcripts of 
ski were expressed with a peak at mid Gl during hematopoi- 
esis, in contrast to the invariable expression of ski mRNA 
during myogenesis (Fig. 1). But the invariably low abundance 
of c-ski mRNA during differentiation does not necessarily 
mean that c-ski is not involved in myogenic process of 
C2Cl2 cells. Posttranslational modification such as phosphor- 
ylation [33] and/or cooperative interaction with other factors 
[34,35] may be required on ski protein to confer a potential 
activity. 
Muscle differentiation conditions also caused the transient 
expression of snoN in fibroblastic C3HlOTl/2 cells, irrespec- 
tive of whether they were defective for myogenesis. Thus, 
snoN expression is not sufficient to compel C3HlOTl/2 to 
undergo myogenesis, consistent with the observation that 
overexpression of exogenous snoN in fibroblastic C3HlOTII 
2 cells did not induce myogenesis (unpublished observation) 
although overexpression of MyoD family proteins alone did 
[ 15,16,36]. An unknown factor downstream of snoN protein is 
needed for myogenesis to be triggered; the factor is not pres- 
ent in fibroblastic C3HlOT1/2 cells but in myoblast C2C12 
cells. In this context, it seems intriguing that snoN protein 
is localized in the nucleus [4]and possibly involved in tran- 
scriptional regulation by formation of a heterodimer complex 
with c-ski [37]. 
Investigation of the mechanism that mediates the exit from 
the cell division cycle to the quiescent state (GO) should lead 
to a knowledge of how to determine the fate of cells, growth 
or differentiation. The critical step in this process remains 
enigma and it remains unknown even whether a discrete 
boundary exists between the Gl and GO phases. The biologi- 
cal consequence of the transient increase in snoN expression is 
also unknown at present, but may provide a clue to elucida- 
tion of the process underlying GO entry. 
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